Published in Apoptosis on November 01, 2008
A large and accurate collection of peptidase cleavages in the MEROPS database. Database (Oxford) (2009) 1.28
Proteome-wide substrate analysis indicates substrate exclusion as a mechanism to generate caspase-7 versus caspase-3 specificity. Mol Cell Proteomics (2009) 1.27
L2' loop is critical for caspase-7 active site formation. Protein Sci (2009) 1.11
Degradomics reveals that cleavage specificity profiles of caspase-2 and effector caspases are alike. J Biol Chem (2012) 0.92
Specificity of a protein-protein interface: local dynamics direct substrate recognition of effector caspases. Proteins (2013) 0.86
An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation. Mol Cell Proteomics (2014) 0.84
A method to evaluate genome-wide methylation in archival formalin-fixed, paraffin-embedded ovarian epithelial cells. PLoS One (2014) 0.82
A closed conformation of the Caenorhabditis elegans separase-securin complex. Open Biol (2016) 0.81
Identification of functional regions defining different activity in caspase-3 and caspase-7 within cells. J Biol Chem (2010) 0.79
Structural Insights into Separase Architecture and Substrate Recognition through Computational Modelling of Caspase-Like and Death Domains. PLoS Comput Biol (2015) 0.78
Modifying caspase-3 activity by altering allosteric networks. Biochemistry (2014) 0.78
Molecular determinants involved in activation of caspase 7. Biosci Rep (2011) 0.78
Small Molecule Active Site Directed Tools for Studying Human Caspases. Chem Rev (2015) 0.77
Characterization of a novel domain 'GATE' in the ABC protein DrrA and its role in drug efflux by the DrrAB complex. Biochem Biophys Res Commun (2015) 0.75
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
SHELXL: high-resolution refinement. Methods Enzymol (1997) 43.04
Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins (2003) 32.38
Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr (2005) 29.38
Raster3D Version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr D Biol Crystallogr (1994) 17.44
A graphical user interface to the CCP4 program suite. Acta Crystallogr D Biol Crystallogr (2003) 13.43
A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem (1997) 9.97
Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science (2006) 6.55
The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J (2004) 4.85
Structure and mechanism of interleukin-1 beta converting enzyme. Nature (1994) 4.44
Substrate specificities of caspase family proteases. J Biol Chem (1997) 4.16
Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell (2003) 4.07
Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ (2003) 3.59
Caspase substrates. Cell Death Differ (2006) 2.79
Caspases: pharmacological manipulation of cell death. J Clin Invest (2005) 2.10
Purification and catalytic properties of human caspase family members. Cell Death Differ (1999) 1.96
The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity. Chem Biol (2000) 1.82
Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology (2003) 1.56
Apoptosis-based therapies and drug targets. Cell Death Differ (2005) 1.51
Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ (2004) 1.44
Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant (2007) 1.36
The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res (2005) 1.33
Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci (2001) 1.31
Crystal structure of caspase-2, apical initiator of the intrinsic apoptotic pathway. J Biol Chem (2003) 1.23
CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res (2005) 1.20
Plasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysis. FEBS J (2007) 1.09
Morphological aspects of apoptosis in heart diseases. J Cell Mol Med (2006) 1.09
Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology (2006) 0.98
Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition. J Mol Biol (2006) 0.91
Analysis of six protein structures predicted by comparative modeling techniques. Proteins (1995) 0.91
Increased caspase activation in peripheral blood mononuclear cells of patients with Alzheimer's disease. Exp Neurol (2004) 0.89
Caspases in myocardial infarction. Adv Clin Chem (2007) 0.86
Natural and synthetic inhibitors of caspases: targets for novel drugs. Curr Drug Targets CNS Neurol Disord (2004) 0.82
Crystal structures of Tcl1 family oncoproteins and their conserved surface features. ScientificWorldJournal (2002) 5.20
Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature (2002) 3.92
Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation (2003) 3.30
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother (2003) 3.23
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases. Circ Res (2003) 2.44
High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol (2004) 2.21
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc Chem Res (2007) 2.16
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J Med Chem (2006) 1.75
Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res (2002) 1.70
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem (2006) 1.69
Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol (2006) 1.66
HIV-1 protease: structure, dynamics, and inhibition. Adv Pharmacol (2007) 1.60
A hexane fraction of American ginseng suppresses mouse colitis and associated colon cancer: anti-inflammatory and proapoptotic mechanisms. Cancer Prev Res (Phila) (2012) 1.55
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J (2005) 1.46
Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem (2008) 1.44
Critical role for the alpha-1B adrenergic receptor at the sympathetic neuroeffector junction. Hypertension (2004) 1.44
Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One (2010) 1.41
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance. ChemMedChem (2006) 1.40
HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses (2009) 1.37
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother (2007) 1.34
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. FEBS J (2010) 1.30
Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem (2002) 1.30
Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins (2002) 1.30
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins (2007) 1.28
Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur J Biochem (2004) 1.27
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol (2005) 1.22
HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. Biochemistry (2012) 1.20
Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function. Proc Natl Acad Sci U S A (2012) 1.18
Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors. Proc Natl Acad Sci U S A (2011) 1.18
Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res (2012) 1.16
SIRT1 negatively regulates the activities, functions, and protein levels of hMOF and TIP60. Mol Cell Biol (2012) 1.15
Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. J Mol Biol (2006) 1.14
Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends. J Biol Chem (2005) 1.13
Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci U S A (2012) 1.13
Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. J Med Chem (2007) 1.12
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors. ChemMedChem (2010) 1.11
Arabidopsis snc2-1D activates receptor-like protein-mediated immunity transduced through WRKY70. Plant Cell (2010) 1.11
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res (2010) 1.10
Plasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysis. FEBS J (2007) 1.09
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A (2013) 1.09
Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. J Mol Biol (2008) 1.09
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV. Angew Chem Int Ed Engl (2012) 1.08
Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol (2003) 1.03
Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry (2007) 1.03
Geometric criteria of hydrogen bonds in proteins and identification of "bifurcated" hydrogen bonds. Protein Eng (2002) 1.02
Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia (2010) 1.02
Covalent reaction intermediate revealed in crystal structure of the Geobacillus stearothermophilus carboxylesterase Est30. J Mol Biol (2004) 1.02
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. J Med Chem (2008) 1.02
Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance. Protein Sci (2010) 1.01
Defining the DNA substrate binding sites on HIV-1 integrase. J Mol Biol (2008) 1.01
cAMP-dependent protein kinase phosphorylation produces interdomain movement in SUR2B leading to activation of the vascular KATP channel. J Biol Chem (2008) 1.00
Biochemical and structural analysis of substrate promiscuity in plant Mg2+-dependent O-methyltransferases. J Mol Biol (2008) 0.99
H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes. Nat Struct Mol Biol (2012) 0.98
Nanostructured catalysts in fuel cells. Nanotechnology (2010) 0.98
Archaeal and bacterial diversity in hot springs on the Tibetan Plateau, China. Extremophiles (2011) 0.96
Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease. J Med Chem (2013) 0.96
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. J Med Chem (2011) 0.96
Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer (2010) 0.96
Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. J Biol Chem (2013) 0.95
Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease. J Mol Biol (2008) 0.95
Terminal interface conformations modulate dimer stability prior to amino terminal autoprocessing of HIV-1 protease. Biochemistry (2012) 0.95
TaCIPK29, a CBL-interacting protein kinase gene from wheat, confers salt stress tolerance in transgenic tobacco. PLoS One (2013) 0.93
Seeing citrulline: development of a phenylglyoxal-based probe to visualize protein citrullination. J Am Chem Soc (2012) 0.93
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol (2013) 0.93
Behavioral changes and dopaminergic dysregulation in mice lacking the nuclear receptor Rev-erbα. Mol Endocrinol (2014) 0.92
Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease. J Biol Chem (2004) 0.92
Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis. Carcinogenesis (2010) 0.92
Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition. J Mol Biol (2006) 0.91
Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands. ACS Med Chem Lett (2011) 0.91
The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One (2013) 0.91
Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. J Virol Methods (2004) 0.91